Andres Henao Martinez
Concepts (485)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Chagas Disease | 13 | 2023 | 34 | 7.410 |
Why?
| Chagas Cardiomyopathy | 7 | 2023 | 22 | 4.490 |
Why?
| Meningitis, Cryptococcal | 8 | 2024 | 28 | 3.770 |
Why?
| Cryptococcosis | 6 | 2023 | 23 | 3.540 |
Why?
| Opportunistic Infections | 4 | 2024 | 43 | 2.690 |
Why?
| Trypanosoma cruzi | 6 | 2023 | 23 | 2.480 |
Why?
| Cryptococcus neoformans | 4 | 2024 | 18 | 1.910 |
Why?
| Invasive Pulmonary Aspergillosis | 2 | 2023 | 3 | 1.770 |
Why?
| HIV Infections | 10 | 2024 | 2469 | 1.750 |
Why?
| Travel | 6 | 2021 | 121 | 1.650 |
Why?
| Strongyloidiasis | 2 | 2024 | 4 | 1.470 |
Why?
| Cryptococcus | 2 | 2024 | 8 | 1.460 |
Why?
| Immunocompromised Host | 6 | 2024 | 195 | 1.370 |
Why?
| Stroke, Lacunar | 2 | 2019 | 4 | 1.290 |
Why?
| Humans | 103 | 2024 | 114662 | 1.240 |
Why?
| Tuberculosis | 2 | 2022 | 241 | 1.230 |
Why?
| Hospitalization | 7 | 2024 | 1751 | 1.230 |
Why?
| Transients and Migrants | 3 | 2023 | 22 | 1.200 |
Why?
| Candidemia | 2 | 2024 | 7 | 1.190 |
Why?
| Cardiomyopathies | 2 | 2021 | 298 | 1.160 |
Why?
| Yellow Fever | 3 | 2022 | 7 | 1.100 |
Why?
| Bacteremia | 5 | 2023 | 160 | 1.090 |
Why?
| Infectious Disease Transmission, Vertical | 2 | 2019 | 152 | 1.050 |
Why?
| Candida | 2 | 2024 | 32 | 1.020 |
Why?
| Glucocorticoids | 3 | 2024 | 532 | 1.010 |
Why?
| Central Nervous System Neoplasms | 2 | 2018 | 126 | 1.000 |
Why?
| Antifungal Agents | 8 | 2023 | 128 | 0.990 |
Why?
| Adult | 36 | 2024 | 30544 | 0.980 |
Why?
| Risk Factors | 15 | 2024 | 8632 | 0.970 |
Why?
| Parasitemia | 2 | 2015 | 9 | 0.940 |
Why?
| Pneumocystis | 1 | 2024 | 6 | 0.930 |
Why?
| Mycoses | 1 | 2024 | 67 | 0.910 |
Why?
| Pneumonia, Pneumocystis | 1 | 2024 | 24 | 0.910 |
Why?
| Nitroimidazoles | 1 | 2023 | 6 | 0.890 |
Why?
| Pulmonary Aspergillosis | 1 | 2023 | 3 | 0.890 |
Why?
| Male | 44 | 2024 | 55583 | 0.860 |
Why?
| Myocarditis | 2 | 2016 | 93 | 0.860 |
Why?
| Pneumonia, Viral | 7 | 2020 | 338 | 0.860 |
Why?
| Coronavirus Infections | 7 | 2020 | 330 | 0.860 |
Why?
| Anemia, Aplastic | 1 | 2023 | 30 | 0.850 |
Why?
| AIDS-Related Opportunistic Infections | 1 | 2024 | 116 | 0.850 |
Why?
| Immunotherapy, Adoptive | 1 | 2024 | 184 | 0.830 |
Why?
| Enterobacteriaceae Infections | 2 | 2013 | 32 | 0.830 |
Why?
| Zoonoses | 2 | 2024 | 21 | 0.820 |
Why?
| Virus Diseases | 1 | 2024 | 195 | 0.810 |
Why?
| Anti-Bacterial Agents | 8 | 2023 | 1481 | 0.800 |
Why?
| Antigens, Fungal | 2 | 2024 | 24 | 0.770 |
Why?
| Neglected Diseases | 1 | 2020 | 4 | 0.740 |
Why?
| Mycobacterium Infections | 2 | 2018 | 61 | 0.720 |
Why?
| Hepatitis | 1 | 2020 | 45 | 0.710 |
Why?
| Middle Aged | 23 | 2024 | 26733 | 0.700 |
Why?
| United States | 19 | 2024 | 12181 | 0.700 |
Why?
| Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.690 |
Why?
| Heart Aneurysm | 1 | 2019 | 8 | 0.680 |
Why?
| Epidemics | 1 | 2020 | 69 | 0.670 |
Why?
| Massive Hepatic Necrosis | 1 | 2019 | 3 | 0.660 |
Why?
| Aneurysm, False | 1 | 2019 | 45 | 0.650 |
Why?
| Hepatitis A | 1 | 2019 | 26 | 0.650 |
Why?
| Neisseria gonorrhoeae | 1 | 2019 | 20 | 0.640 |
Why?
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 2 | 0.640 |
Why?
| Sarcoma, Myeloid | 1 | 2018 | 4 | 0.640 |
Why?
| Hematoma, Subdural | 1 | 2018 | 16 | 0.630 |
Why?
| Female | 35 | 2024 | 59493 | 0.620 |
Why?
| Skin | 3 | 2022 | 655 | 0.620 |
Why?
| Plasmodium falciparum | 1 | 2018 | 27 | 0.600 |
Why?
| Malaria, Falciparum | 1 | 2018 | 25 | 0.600 |
Why?
| Fever | 2 | 2020 | 280 | 0.600 |
Why?
| Gonorrhea | 1 | 2019 | 54 | 0.600 |
Why?
| Renal Insufficiency | 1 | 2020 | 137 | 0.600 |
Why?
| Chromoblastomycosis | 1 | 2017 | 1 | 0.600 |
Why?
| Dyspnea | 1 | 2019 | 211 | 0.600 |
Why?
| Retrospective Studies | 12 | 2024 | 12546 | 0.590 |
Why?
| Hand Dermatoses | 1 | 2017 | 7 | 0.590 |
Why?
| Delayed Diagnosis | 1 | 2018 | 70 | 0.590 |
Why?
| Population Groups | 1 | 2018 | 57 | 0.590 |
Why?
| Meningioma | 1 | 2018 | 77 | 0.580 |
Why?
| Heart Failure | 2 | 2022 | 1945 | 0.580 |
Why?
| Meningeal Neoplasms | 1 | 2018 | 87 | 0.580 |
Why?
| Medically Uninsured | 1 | 2018 | 121 | 0.570 |
Why?
| Osteomyelitis | 1 | 2019 | 105 | 0.570 |
Why?
| Abscess | 1 | 2018 | 72 | 0.570 |
Why?
| Pandemics | 10 | 2023 | 1317 | 0.570 |
Why?
| Milk | 1 | 2018 | 124 | 0.560 |
Why?
| Poliomyelitis | 3 | 2022 | 27 | 0.550 |
Why?
| Latin America | 6 | 2022 | 69 | 0.550 |
Why?
| Prisons | 4 | 2021 | 72 | 0.540 |
Why?
| Trichuriasis | 1 | 2016 | 4 | 0.540 |
Why?
| Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.530 |
Why?
| Pregnancy Complications, Hematologic | 1 | 2016 | 16 | 0.530 |
Why?
| Lymphocytosis | 1 | 2016 | 9 | 0.530 |
Why?
| Enterobacteriaceae | 2 | 2013 | 32 | 0.530 |
Why?
| Neoplasms, Unknown Primary | 1 | 2016 | 12 | 0.530 |
Why?
| Parotid Neoplasms | 1 | 2016 | 14 | 0.530 |
Why?
| Occupational Diseases | 1 | 2017 | 128 | 0.520 |
Why?
| Diphyllobothriasis | 1 | 2015 | 2 | 0.510 |
Why?
| Diphyllobothrium | 1 | 2015 | 2 | 0.510 |
Why?
| Pre-Exposure Prophylaxis | 1 | 2018 | 179 | 0.510 |
Why?
| Colombia | 4 | 2020 | 34 | 0.510 |
Why?
| Plasmablastic Lymphoma | 1 | 2015 | 6 | 0.510 |
Why?
| Insect Vectors | 1 | 2015 | 27 | 0.510 |
Why?
| Gamma Rays | 1 | 2015 | 48 | 0.500 |
Why?
| Plasma Cells | 1 | 2015 | 56 | 0.500 |
Why?
| Transplants | 1 | 2015 | 36 | 0.490 |
Why?
| Lymphoma | 1 | 2016 | 177 | 0.480 |
Why?
| Anemia | 1 | 2016 | 143 | 0.480 |
Why?
| Aged | 12 | 2024 | 19069 | 0.480 |
Why?
| Heart Ventricles | 1 | 2019 | 712 | 0.470 |
Why?
| Bone Marrow | 1 | 2016 | 243 | 0.470 |
Why?
| Environmental Exposure | 1 | 2018 | 372 | 0.470 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2023 | 398 | 0.460 |
Why?
| Thrombocytopenia | 1 | 2016 | 177 | 0.460 |
Why?
| Transplant Recipients | 1 | 2015 | 140 | 0.450 |
Why?
| Research | 1 | 2016 | 394 | 0.430 |
Why?
| Myocardial Contraction | 1 | 2015 | 313 | 0.430 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 4 | 2023 | 191 | 0.430 |
Why?
| Lymphoma, Primary Effusion | 1 | 2013 | 3 | 0.430 |
Why?
| Thrombocytosis | 1 | 2013 | 6 | 0.430 |
Why?
| Betacoronavirus | 6 | 2020 | 250 | 0.420 |
Why?
| Lymphoma, AIDS-Related | 1 | 2013 | 13 | 0.420 |
Why?
| Herpesvirus 8, Human | 1 | 2013 | 61 | 0.410 |
Why?
| Antigens, Protozoan | 1 | 2012 | 19 | 0.410 |
Why?
| Acinetobacter Infections | 1 | 2012 | 10 | 0.410 |
Why?
| Acinetobacter | 1 | 2012 | 13 | 0.410 |
Why?
| Proctitis | 1 | 2012 | 5 | 0.400 |
Why?
| Healthcare Disparities | 3 | 2024 | 480 | 0.400 |
Why?
| Herpes Genitalis | 1 | 2012 | 16 | 0.400 |
Why?
| H-2 Antigens | 1 | 2012 | 110 | 0.400 |
Why?
| Herpesvirus 2, Human | 1 | 2012 | 27 | 0.400 |
Why?
| Cellulitis | 1 | 2012 | 45 | 0.400 |
Why?
| Animals | 15 | 2024 | 31699 | 0.390 |
Why?
| Isoxazoles | 1 | 2012 | 51 | 0.390 |
Why?
| Treatment Outcome | 11 | 2024 | 9088 | 0.390 |
Why?
| Yellow Fever Vaccine | 2 | 2022 | 6 | 0.390 |
Why?
| Severe Dengue | 1 | 2011 | 9 | 0.390 |
Why?
| Acyclovir | 1 | 2012 | 100 | 0.380 |
Why?
| Herpesviridae Infections | 1 | 2013 | 138 | 0.380 |
Why?
| Emigration and Immigration | 2 | 2022 | 44 | 0.380 |
Why?
| Magnetic Resonance Imaging | 2 | 2019 | 3046 | 0.370 |
Why?
| B-Lymphocytes | 1 | 2016 | 766 | 0.370 |
Why?
| Poliovirus | 2 | 2022 | 77 | 0.360 |
Why?
| Pancreatitis | 1 | 2011 | 107 | 0.360 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2094 | 0.350 |
Why?
| Young Adult | 9 | 2024 | 10466 | 0.350 |
Why?
| Repressor Proteins | 1 | 2013 | 366 | 0.340 |
Why?
| Moraxellaceae Infections | 1 | 2009 | 2 | 0.340 |
Why?
| Moraxella | 1 | 2009 | 5 | 0.340 |
Why?
| Lung Diseases | 2 | 2018 | 701 | 0.340 |
Why?
| Acute Lung Injury | 1 | 2013 | 298 | 0.330 |
Why?
| Aged, 80 and over | 5 | 2024 | 6345 | 0.330 |
Why?
| Biomarkers, Tumor | 1 | 2015 | 1040 | 0.330 |
Why?
| Lupus Nephritis | 1 | 2009 | 52 | 0.330 |
Why?
| Fluconazole | 3 | 2023 | 16 | 0.320 |
Why?
| Arthritis, Infectious | 1 | 2009 | 49 | 0.320 |
Why?
| Pulmonary Emphysema | 1 | 2011 | 268 | 0.310 |
Why?
| Staphylococcal Infections | 3 | 2023 | 340 | 0.310 |
Why?
| Immunoglobulin G | 3 | 2023 | 770 | 0.310 |
Why?
| Presenilin-1 | 1 | 2008 | 27 | 0.300 |
Why?
| Fatal Outcome | 2 | 2019 | 284 | 0.300 |
Why?
| Engineering | 1 | 2018 | 25 | 0.300 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1355 | 0.290 |
Why?
| Social Responsibility | 1 | 2018 | 45 | 0.290 |
Why?
| Public Health | 3 | 2020 | 433 | 0.280 |
Why?
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 63 | 0.280 |
Why?
| Echinocandins | 2 | 2023 | 8 | 0.280 |
Why?
| Mycobacterium | 2 | 2018 | 103 | 0.270 |
Why?
| Time Factors | 3 | 2024 | 6115 | 0.270 |
Why?
| Acute Kidney Injury | 1 | 2013 | 637 | 0.270 |
Why?
| Antiviral Agents | 1 | 2012 | 645 | 0.270 |
Why?
| Attitude | 1 | 2018 | 229 | 0.260 |
Why?
| Sepsis | 2 | 2022 | 509 | 0.260 |
Why?
| Clinical Trials as Topic | 2 | 2020 | 931 | 0.260 |
Why?
| HIV | 2 | 2018 | 208 | 0.260 |
Why?
| Electrocardiography | 2 | 2019 | 560 | 0.260 |
Why?
| Propensity Score | 2 | 2023 | 224 | 0.250 |
Why?
| Shock, Septic | 2 | 2021 | 186 | 0.250 |
Why?
| Incidence | 2 | 2024 | 2313 | 0.250 |
Why?
| Candida tropicalis | 1 | 2024 | 2 | 0.240 |
Why?
| Polymorphism, Genetic | 1 | 2008 | 610 | 0.240 |
Why?
| Insect Bites and Stings | 1 | 2024 | 13 | 0.240 |
Why?
| Colorado | 3 | 2020 | 4099 | 0.240 |
Why?
| Strongyloides stercoralis | 1 | 2024 | 2 | 0.230 |
Why?
| Alanine | 1 | 2024 | 104 | 0.230 |
Why?
| Teicoplanin | 2 | 2023 | 17 | 0.230 |
Why?
| Peru | 2 | 2024 | 54 | 0.220 |
Why?
| World Health Organization | 2 | 2021 | 102 | 0.220 |
Why?
| Toxoplasma | 1 | 2023 | 31 | 0.220 |
Why?
| Toxoplasmosis | 1 | 2023 | 31 | 0.220 |
Why?
| Meningoencephalitis | 1 | 2023 | 24 | 0.220 |
Why?
| Predictive Value of Tests | 2 | 2019 | 1796 | 0.220 |
Why?
| Voriconazole | 1 | 2023 | 24 | 0.220 |
Why?
| Students | 1 | 2018 | 502 | 0.210 |
Why?
| Pregnancy | 4 | 2024 | 5518 | 0.210 |
Why?
| Pyridones | 1 | 2024 | 123 | 0.210 |
Why?
| Rabies | 1 | 2022 | 1 | 0.210 |
Why?
| Rabies Vaccines | 1 | 2022 | 2 | 0.210 |
Why?
| Tomography, X-Ray Computed | 4 | 2019 | 2285 | 0.210 |
Why?
| Alzheimer Disease | 1 | 2008 | 442 | 0.210 |
Why?
| Tenofovir | 1 | 2024 | 204 | 0.210 |
Why?
| Prognosis | 3 | 2022 | 3329 | 0.210 |
Why?
| Antiparasitic Agents | 1 | 2022 | 3 | 0.210 |
Why?
| Glycopeptides | 1 | 2023 | 43 | 0.210 |
Why?
| Kaplan-Meier Estimate | 1 | 2024 | 811 | 0.200 |
Why?
| Drug Therapy, Combination | 2 | 2018 | 951 | 0.200 |
Why?
| Dog Diseases | 1 | 2022 | 41 | 0.200 |
Why?
| Sexually Transmitted Diseases | 1 | 2024 | 155 | 0.200 |
Why?
| Americas | 1 | 2022 | 19 | 0.200 |
Why?
| Disease Notification | 1 | 2022 | 13 | 0.200 |
Why?
| Rural Population | 2 | 2022 | 446 | 0.200 |
Why?
| Italy | 1 | 2022 | 92 | 0.200 |
Why?
| Travel Medicine | 2 | 2020 | 5 | 0.200 |
Why?
| Staphylococcal Skin Infections | 2 | 2012 | 29 | 0.190 |
Why?
| Leprosy | 1 | 2021 | 10 | 0.190 |
Why?
| Proportional Hazards Models | 1 | 2024 | 1075 | 0.190 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 217 | 0.190 |
Why?
| Population Dynamics | 1 | 2022 | 123 | 0.190 |
Why?
| Case-Control Studies | 3 | 2018 | 3003 | 0.190 |
Why?
| Weight Gain | 1 | 2024 | 453 | 0.180 |
Why?
| Leishmania guyanensis | 1 | 2020 | 1 | 0.180 |
Why?
| Leishmaniasis, Cutaneous | 1 | 2020 | 7 | 0.180 |
Why?
| Phosphorylcholine | 1 | 2020 | 17 | 0.180 |
Why?
| Antiprotozoal Agents | 1 | 2020 | 12 | 0.180 |
Why?
| Anti-Inflammatory Agents | 1 | 2024 | 447 | 0.180 |
Why?
| Pericarditis | 1 | 2020 | 9 | 0.180 |
Why?
| Personal Protective Equipment | 1 | 2021 | 49 | 0.180 |
Why?
| Developing Countries | 1 | 2022 | 235 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2022 | 1139 | 0.180 |
Why?
| Receptors, Interleukin-6 | 1 | 2020 | 34 | 0.180 |
Why?
| Communicable Diseases, Emerging | 1 | 2020 | 28 | 0.170 |
Why?
| Sexual and Gender Minorities | 1 | 2022 | 138 | 0.170 |
Why?
| Africa | 1 | 2020 | 94 | 0.170 |
Why?
| Immunosuppressive Agents | 1 | 2024 | 646 | 0.170 |
Why?
| Immunization, Secondary | 1 | 2020 | 82 | 0.170 |
Why?
| Prospective Studies | 4 | 2023 | 6219 | 0.170 |
Why?
| Databases, Factual | 1 | 2024 | 1125 | 0.170 |
Why?
| Late Onset Disorders | 1 | 2019 | 2 | 0.170 |
Why?
| Genetic Predisposition to Disease | 1 | 2008 | 2085 | 0.170 |
Why?
| Proteinuria | 1 | 2020 | 77 | 0.170 |
Why?
| Bolivia | 1 | 2019 | 62 | 0.170 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2020 | 61 | 0.170 |
Why?
| Infection Control | 1 | 2021 | 135 | 0.170 |
Why?
| Medical Errors | 1 | 2020 | 85 | 0.160 |
Why?
| Neoplasms | 1 | 2013 | 2097 | 0.160 |
Why?
| Acute Disease | 2 | 2012 | 911 | 0.160 |
Why?
| Vulnerable Populations | 1 | 2020 | 133 | 0.160 |
Why?
| Invasive Fungal Infections | 1 | 2019 | 10 | 0.160 |
Why?
| Observational Studies as Topic | 1 | 2019 | 90 | 0.160 |
Why?
| Amphotericin B | 1 | 2019 | 29 | 0.160 |
Why?
| Echocardiography | 2 | 2020 | 553 | 0.160 |
Why?
| Cryptococcus gattii | 1 | 2018 | 1 | 0.160 |
Why?
| Sex Factors | 1 | 2024 | 1715 | 0.160 |
Why?
| Stroke Volume | 1 | 2021 | 504 | 0.160 |
Why?
| Dermatitis | 1 | 2018 | 17 | 0.160 |
Why?
| Antibodies, Neutralizing | 1 | 2020 | 221 | 0.160 |
Why?
| Speech Disorders | 1 | 2018 | 30 | 0.160 |
Why?
| Computed Tomography Angiography | 1 | 2019 | 97 | 0.160 |
Why?
| Emigrants and Immigrants | 1 | 2020 | 107 | 0.160 |
Why?
| Respiration, Artificial | 1 | 2022 | 529 | 0.150 |
Why?
| Africa, Western | 1 | 2018 | 16 | 0.150 |
Why?
| California | 1 | 2019 | 353 | 0.150 |
Why?
| Ventricular Function, Left | 1 | 2021 | 467 | 0.150 |
Why?
| Administration, Intravenous | 1 | 2019 | 124 | 0.150 |
Why?
| Longitudinal Studies | 2 | 2019 | 2387 | 0.150 |
Why?
| Raw Foods | 1 | 2018 | 2 | 0.150 |
Why?
| Arrhythmias, Cardiac | 1 | 2020 | 279 | 0.150 |
Why?
| Administration, Oral | 2 | 2020 | 728 | 0.150 |
Why?
| Prisoners | 1 | 2020 | 124 | 0.150 |
Why?
| Itraconazole | 1 | 2017 | 7 | 0.150 |
Why?
| Cytokines | 2 | 2022 | 1840 | 0.150 |
Why?
| Food Microbiology | 1 | 2018 | 57 | 0.150 |
Why?
| Georgia | 1 | 2017 | 62 | 0.150 |
Why?
| Hyponatremia | 1 | 2018 | 37 | 0.150 |
Why?
| Research Design | 2 | 2021 | 928 | 0.140 |
Why?
| Antibodies, Viral | 1 | 2020 | 520 | 0.140 |
Why?
| Farmers | 1 | 2017 | 42 | 0.140 |
Why?
| Patient Safety | 1 | 2020 | 277 | 0.140 |
Why?
| Disability Evaluation | 1 | 2019 | 271 | 0.140 |
Why?
| Patient Acceptance of Health Care | 1 | 2022 | 681 | 0.140 |
Why?
| Socioeconomic Factors | 2 | 2020 | 1078 | 0.140 |
Why?
| Brain | 1 | 2008 | 2371 | 0.140 |
Why?
| Mebendazole | 1 | 2016 | 2 | 0.130 |
Why?
| Strongyloides | 1 | 2016 | 2 | 0.130 |
Why?
| Trichuris | 1 | 2016 | 3 | 0.130 |
Why?
| Albendazole | 1 | 2016 | 4 | 0.130 |
Why?
| Pharmacists | 1 | 2019 | 233 | 0.130 |
Why?
| Ivermectin | 1 | 2016 | 9 | 0.130 |
Why?
| Interleukin-6 | 1 | 2020 | 676 | 0.130 |
Why?
| Vaccination | 2 | 2022 | 1204 | 0.130 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 238 | 0.130 |
Why?
| Evidence-Based Medicine | 1 | 2020 | 668 | 0.130 |
Why?
| Hematocrit | 1 | 2016 | 87 | 0.130 |
Why?
| Hospitals, University | 1 | 2016 | 172 | 0.130 |
Why?
| Mental Disorders | 1 | 2023 | 892 | 0.130 |
Why?
| Praziquantel | 1 | 2015 | 5 | 0.130 |
Why?
| Arachis | 1 | 2017 | 146 | 0.130 |
Why?
| Disease Outbreaks | 3 | 2023 | 307 | 0.130 |
Why?
| Anthelmintics | 1 | 2015 | 9 | 0.130 |
Why?
| Diagnosis, Differential | 1 | 2020 | 1342 | 0.130 |
Why?
| Clone Cells | 1 | 2016 | 247 | 0.130 |
Why?
| Recurrence | 1 | 2018 | 935 | 0.130 |
Why?
| Genotype | 2 | 2012 | 1760 | 0.120 |
Why?
| Lipids | 1 | 2019 | 580 | 0.120 |
Why?
| Academic Medical Centers | 1 | 2018 | 411 | 0.120 |
Why?
| Migraine Disorders | 1 | 2016 | 82 | 0.120 |
Why?
| Herpesvirus 4, Human | 1 | 2015 | 125 | 0.120 |
Why?
| Health Care Costs | 1 | 2018 | 381 | 0.120 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 115 | 0.120 |
Why?
| Hearing Loss | 1 | 2018 | 183 | 0.120 |
Why?
| Frontal Lobe | 1 | 2015 | 141 | 0.120 |
Why?
| Adrenal Cortex Hormones | 1 | 2018 | 497 | 0.120 |
Why?
| Biopsy | 2 | 2020 | 1036 | 0.120 |
Why?
| Heart Transplantation | 1 | 2020 | 665 | 0.120 |
Why?
| Multivariate Analysis | 1 | 2018 | 1430 | 0.110 |
Why?
| Health Status Disparities | 3 | 2020 | 200 | 0.110 |
Why?
| Hemoglobins | 1 | 2016 | 315 | 0.110 |
Why?
| Delivery of Health Care | 1 | 2021 | 833 | 0.110 |
Why?
| Disease Progression | 2 | 2012 | 2380 | 0.110 |
Why?
| Child | 6 | 2023 | 18412 | 0.110 |
Why?
| Feces | 1 | 2015 | 373 | 0.110 |
Why?
| Parasite Load | 1 | 2013 | 7 | 0.110 |
Why?
| APACHE | 1 | 2013 | 58 | 0.110 |
Why?
| Mycoplasma hominis | 1 | 2012 | 4 | 0.110 |
Why?
| Mycoplasma Infections | 1 | 2012 | 13 | 0.110 |
Why?
| Intestines | 1 | 2016 | 326 | 0.110 |
Why?
| Anti-HIV Agents | 2 | 2024 | 666 | 0.110 |
Why?
| Klebsiella Infections | 1 | 2013 | 23 | 0.110 |
Why?
| Logistic Models | 1 | 2018 | 1841 | 0.100 |
Why?
| Comorbidity | 2 | 2022 | 1448 | 0.100 |
Why?
| Platelet Count | 1 | 2013 | 81 | 0.100 |
Why?
| Syncope | 1 | 2013 | 37 | 0.100 |
Why?
| Molecular Typing | 1 | 2012 | 18 | 0.100 |
Why?
| Clindamycin | 1 | 2012 | 12 | 0.100 |
Why?
| Serratia Infections | 1 | 2012 | 6 | 0.100 |
Why?
| Linkage Disequilibrium | 1 | 2013 | 245 | 0.100 |
Why?
| Serratia marcescens | 1 | 2012 | 12 | 0.100 |
Why?
| Central America | 2 | 2023 | 16 | 0.100 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2013 | 71 | 0.100 |
Why?
| Mice, Inbred BALB C | 1 | 2015 | 1143 | 0.100 |
Why?
| Thoracic Vertebrae | 1 | 2012 | 68 | 0.100 |
Why?
| Disease Eradication | 2 | 2022 | 4 | 0.100 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2015 | 445 | 0.100 |
Why?
| Viral Load | 2 | 2024 | 405 | 0.100 |
Why?
| Hedgehog Proteins | 1 | 2013 | 172 | 0.100 |
Why?
| Prevalence | 1 | 2018 | 2251 | 0.100 |
Why?
| Microscopy | 1 | 2013 | 125 | 0.100 |
Why?
| Blister | 1 | 2011 | 43 | 0.100 |
Why?
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 39 | 0.090 |
Why?
| Drug Resistance, Viral | 1 | 2012 | 99 | 0.090 |
Why?
| Drug Resistance, Bacterial | 1 | 2012 | 155 | 0.090 |
Why?
| Poliovirus Vaccine, Oral | 2 | 2022 | 19 | 0.090 |
Why?
| Soft Tissue Infections | 1 | 2011 | 30 | 0.090 |
Why?
| Myocardium | 1 | 2016 | 913 | 0.090 |
Why?
| Cross-Sectional Studies | 2 | 2019 | 4408 | 0.090 |
Why?
| Venezuela | 2 | 2021 | 7 | 0.090 |
Why?
| Spinal Fractures | 1 | 2012 | 75 | 0.090 |
Why?
| Coinfection | 1 | 2012 | 120 | 0.090 |
Why?
| Cohort Studies | 3 | 2022 | 4895 | 0.090 |
Why?
| HIV Seropositivity | 1 | 2011 | 109 | 0.090 |
Why?
| Mice | 3 | 2023 | 14863 | 0.090 |
Why?
| Cross Infection | 1 | 2013 | 197 | 0.090 |
Why?
| Urinary Tract Infections | 1 | 2012 | 134 | 0.090 |
Why?
| Community-Acquired Infections | 1 | 2012 | 141 | 0.090 |
Why?
| Gene Expression | 1 | 2015 | 1421 | 0.090 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2013 | 219 | 0.090 |
Why?
| Surgical Wound Infection | 1 | 2012 | 248 | 0.090 |
Why?
| Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
| Hypertension | 1 | 2018 | 1056 | 0.080 |
Why?
| Piperacillin | 1 | 2009 | 8 | 0.080 |
Why?
| Bacterial Typing Techniques | 1 | 2009 | 40 | 0.080 |
Why?
| Debridement | 1 | 2009 | 73 | 0.080 |
Why?
| Spinal Cord Injuries | 1 | 2012 | 174 | 0.080 |
Why?
| Anti-Infective Agents | 1 | 2011 | 225 | 0.080 |
Why?
| Needs Assessment | 2 | 2021 | 314 | 0.080 |
Why?
| Mortality | 2 | 2021 | 287 | 0.080 |
Why?
| Infusions, Intravenous | 1 | 2009 | 371 | 0.080 |
Why?
| Genes, Dominant | 1 | 2008 | 94 | 0.080 |
Why?
| Socialization | 1 | 2018 | 22 | 0.080 |
Why?
| Global Health | 2 | 2020 | 287 | 0.080 |
Why?
| Chromosome Disorders | 1 | 2008 | 35 | 0.070 |
Why?
| Intensive Care Units | 2 | 2023 | 617 | 0.070 |
Why?
| Point Mutation | 1 | 2008 | 216 | 0.070 |
Why?
| Amino Acid Substitution | 1 | 2008 | 262 | 0.070 |
Why?
| Genetic Markers | 1 | 2008 | 320 | 0.070 |
Why?
| Pedigree | 1 | 2008 | 460 | 0.070 |
Why?
| DNA Mutational Analysis | 1 | 2008 | 372 | 0.070 |
Why?
| Gene Frequency | 1 | 2008 | 477 | 0.070 |
Why?
| Chronic Disease | 1 | 2012 | 1578 | 0.070 |
Why?
| Kidney Failure, Chronic | 1 | 2011 | 489 | 0.070 |
Why?
| Adenocarcinoma | 1 | 2012 | 795 | 0.060 |
Why?
| Amyloid beta-Peptides | 1 | 2008 | 189 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2015 | 2319 | 0.060 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2013 | 1879 | 0.060 |
Why?
| Interviews as Topic | 1 | 2018 | 582 | 0.060 |
Why?
| Mice, Inbred C57BL | 1 | 2015 | 4692 | 0.060 |
Why?
| Genetic Testing | 1 | 2008 | 379 | 0.060 |
Why?
| Registries | 1 | 2013 | 1768 | 0.060 |
Why?
| Wounds and Injuries | 1 | 2012 | 749 | 0.060 |
Why?
| Prostatic Neoplasms | 1 | 2012 | 921 | 0.060 |
Why?
| Moths | 1 | 2024 | 35 | 0.060 |
Why?
| Adolescent | 4 | 2023 | 17841 | 0.060 |
Why?
| Aminobutyrates | 1 | 2024 | 31 | 0.060 |
Why?
| Peptide Fragments | 1 | 2008 | 666 | 0.060 |
Why?
| Antivenins | 1 | 2024 | 56 | 0.060 |
Why?
| Drug Substitution | 1 | 2024 | 46 | 0.060 |
Why?
| Antibodies, Protozoan | 1 | 2023 | 30 | 0.060 |
Why?
| Acetazolamide | 1 | 2023 | 30 | 0.060 |
Why?
| Human Rights | 1 | 2023 | 15 | 0.050 |
Why?
| Seroepidemiologic Studies | 1 | 2023 | 138 | 0.050 |
Why?
| HIV Integrase Inhibitors | 1 | 2024 | 62 | 0.050 |
Why?
| Panama | 1 | 2022 | 9 | 0.050 |
Why?
| Triazoles | 1 | 2024 | 131 | 0.050 |
Why?
| Disease Models, Animal | 1 | 2012 | 3532 | 0.050 |
Why?
| Medicine, Traditional | 1 | 2022 | 23 | 0.050 |
Why?
| Yellow fever virus | 1 | 2022 | 3 | 0.050 |
Why?
| Monkeypox virus | 1 | 2022 | 12 | 0.050 |
Why?
| Standard of Care | 1 | 2023 | 62 | 0.050 |
Why?
| Surveys and Questionnaires | 2 | 2019 | 4622 | 0.050 |
Why?
| Poliovirus Vaccine, Inactivated | 1 | 2022 | 22 | 0.050 |
Why?
| Cell Line | 1 | 2008 | 2636 | 0.050 |
Why?
| Adenine | 1 | 2024 | 219 | 0.050 |
Why?
| Immunoglobulin M | 1 | 2023 | 246 | 0.050 |
Why?
| CD4 Lymphocyte Count | 1 | 2023 | 257 | 0.050 |
Why?
| Mexico | 1 | 2022 | 162 | 0.050 |
Why?
| Vancomycin | 1 | 2023 | 75 | 0.050 |
Why?
| Microbial Sensitivity Tests | 1 | 2023 | 300 | 0.050 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1879 | 0.050 |
Why?
| Curriculum | 1 | 2018 | 819 | 0.050 |
Why?
| Cameroon | 1 | 2021 | 8 | 0.050 |
Why?
| Cuba | 1 | 2021 | 11 | 0.050 |
Why?
| Mycobacterium leprae | 1 | 2021 | 7 | 0.050 |
Why?
| Contact Tracing | 1 | 2021 | 16 | 0.050 |
Why?
| Dogs | 1 | 2022 | 334 | 0.050 |
Why?
| Healthy Volunteers | 1 | 2022 | 197 | 0.050 |
Why?
| Homosexuality, Male | 1 | 2022 | 170 | 0.050 |
Why?
| Inflammation | 2 | 2022 | 2478 | 0.050 |
Why?
| Minority Health | 1 | 2021 | 19 | 0.050 |
Why?
| Minority Groups | 1 | 2022 | 227 | 0.050 |
Why?
| Pregnancy Complications, Infectious | 1 | 2024 | 288 | 0.050 |
Why?
| Meta-Analysis as Topic | 1 | 2021 | 158 | 0.040 |
Why?
| Cardiovascular Infections | 1 | 2020 | 2 | 0.040 |
Why?
| Pericardiocentesis | 1 | 2020 | 9 | 0.040 |
Why?
| History, 17th Century | 1 | 2020 | 15 | 0.040 |
Why?
| Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
| Hemorrhage | 1 | 2024 | 620 | 0.040 |
Why?
| Social Justice | 1 | 2021 | 67 | 0.040 |
Why?
| Signal Transduction | 1 | 2013 | 4512 | 0.040 |
Why?
| Outpatients | 1 | 2023 | 326 | 0.040 |
Why?
| Network Meta-Analysis | 1 | 2020 | 15 | 0.040 |
Why?
| Crowding | 1 | 2020 | 37 | 0.040 |
Why?
| Brazil | 1 | 2020 | 89 | 0.040 |
Why?
| Policy Making | 1 | 2020 | 81 | 0.040 |
Why?
| Communicable Disease Control | 1 | 2020 | 67 | 0.040 |
Why?
| Catheter-Related Infections | 1 | 2020 | 62 | 0.040 |
Why?
| Social Determinants of Health | 1 | 2022 | 135 | 0.040 |
Why?
| History, 21st Century | 1 | 2020 | 159 | 0.040 |
Why?
| Staphylococcus aureus | 1 | 2023 | 389 | 0.040 |
Why?
| Frail Elderly | 1 | 2020 | 106 | 0.040 |
Why?
| Cough | 1 | 2020 | 107 | 0.040 |
Why?
| History, 20th Century | 1 | 2020 | 264 | 0.040 |
Why?
| Southeastern United States | 1 | 2018 | 30 | 0.040 |
Why?
| Nursing Homes | 1 | 2020 | 136 | 0.040 |
Why?
| HIV-1 | 1 | 2024 | 768 | 0.040 |
Why?
| Skilled Nursing Facilities | 1 | 2020 | 121 | 0.040 |
Why?
| Drug Compounding | 1 | 2019 | 89 | 0.040 |
Why?
| Quality Assurance, Health Care | 1 | 2021 | 311 | 0.040 |
Why?
| Immunization Schedule | 1 | 2020 | 184 | 0.040 |
Why?
| Residence Characteristics | 1 | 2020 | 275 | 0.040 |
Why?
| Immunologic Factors | 1 | 2020 | 220 | 0.040 |
Why?
| Critical Illness | 1 | 2023 | 645 | 0.040 |
Why?
| Organ Transplantation | 1 | 2020 | 159 | 0.040 |
Why?
| Urban Population | 1 | 2020 | 397 | 0.040 |
Why?
| Polymerase Chain Reaction | 1 | 2020 | 993 | 0.040 |
Why?
| Risk | 1 | 2020 | 812 | 0.040 |
Why?
| Occupational Exposure | 1 | 2020 | 255 | 0.040 |
Why?
| Hospitals | 1 | 2022 | 581 | 0.040 |
Why?
| Models, Theoretical | 1 | 2020 | 515 | 0.030 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 663 | 0.030 |
Why?
| Mass Screening | 1 | 2022 | 1004 | 0.030 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2011 | 3252 | 0.030 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 17 | 0.030 |
Why?
| Molecular Epidemiology | 1 | 2012 | 62 | 0.020 |
Why?
| Risk Assessment | 1 | 2020 | 2968 | 0.020 |
Why?
| Infant | 1 | 2021 | 7961 | 0.020 |
Why?
| Child, Preschool | 1 | 2021 | 9114 | 0.020 |
Why?
| Lung | 1 | 2020 | 3559 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2011 | 1842 | 0.020 |
Why?
|
|
Henao Martinez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|